Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct:74:101670.
doi: 10.1016/j.trim.2022.101670. Epub 2022 Jul 11.

SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies

Veerle P W M Wijtvliet  1 , Sonja Verheyden  2 , Barbara Depreter  2 , Christine Heylen  3 , Elke Coeman  3 , Steven Abrams  4 , Benedicte Y De Winter  5 , Annick Massart  6 , Rachel Hellemans  6 , Lissa Pipeleers  7 , Frans H J Claas  8 , Kevin K Ariën  9 , Karl Martin Wissing  7 , Daniel Abramowicz  6 , Kristien J Ledeganck  5
Affiliations

SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies

Veerle P W M Wijtvliet et al. Transpl Immunol. 2022 Oct.

Abstract

Background: SARS-CoV-2 vaccination is strongly recommended in kidney transplant recipients (KTR) and dialysis patients. Whether these vaccinations may trigger alloantibodies, is still debated.

Methods: In the current study we evaluated the effect of SARS-CoV-2 mRNA vaccines on anti-Human Leukocyte Antigen (HLA) and 60 anti-non-HLA antibody profiles in clinically stable KTR and dialysis patients. In total, we included 28 KTR, 30 patients on haemodialysis, 25 patients on peritoneal dialysis and 31 controls with a positive seroresponse 16-21 days after the first dose of either the SARS-CoV-2 mRNA BNT162b2 or mRNA-1273 vaccine. Both anti-HLA and anti-non-HLA antibodies were determined prior to vaccination and 21 to 35 days after the second vaccine dose.

Results: Overall, the proportion of patients with detectable anti-HLA antibodies was similar before and after vaccination (class I 14% vs. 16%, p = 0.48; class II 25% before and after vaccination). After vaccination, there was no pattern in 1) additionally detected anti-HLA antibodies, or 2) the levels of pre-existing ones. Additional anti-non-HLA antibodies were detected in 30% of the patients, ranging from 1 to 5 new anti-non-HLA antibodies per patient. However, the clinical significance of anti-non-HLA antibodies is still a matter of debate. To date, only a significant association has been found for anti-non-HLA ARHGDIB antibodies and long-term kidney graft loss. No additionally developed anti-ARHGDIB antibodies or elevated level of existing anti-ARHGDIB antibodies was observed.

Conclusion: The current data indicate that SARS-CoV-2 mRNA vaccination does not induce anti-HLA or anti-non-HLA antibodies, corroborating the importance of vaccinating KTR and dialysis patients.

Keywords: Antibodies; Human leukocyte antigen (HLA); Minor antigen; SARS-CoV-2; Vaccination.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
Flow-chart of patient selection. Abbreviations: CTR = controls; HD = patients on haemodialysis; HLA = human leukocyte antigens; KTR = kidney transplant recipients; PD = patients on peritoneal dialysis.
Fig. 2
Fig. 2
Percentage of patients with positive antibody responses (to at least one bead) pre-vaccination (white) and 1 month after 2-dose SARS-CoV-2 mRNA vaccination (black). P-values were calculated using the McNemar's test with continuity correction. The frequency of anti-HLA antibodies remained overall unchanged post-vaccination in the study group of 114 subjects (28 kidney transplant recipients, 30 patients on haemodialysis, 25 patients on peritoneal dialysis and 31 controls). Abbreviations: CTR = controls; HD = patients on haemodialysis; HLA = human leukocyte antigens; KTR = kidney transplant recipients; PD = patients on peritoneal dialysis.
See this image and copyright information in PMC

References

    1. Anand S., Montez-Rath M., Han J., Bozeman J., Kerschmann R., Beyer P., Parsonnet J., Chertow G.M. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. Lancet. 2020;396(10259):1335–1344. - PMC - PubMed
    1. Cheng Y., Luo R., Wang K., Zhang M., Wang Z., Dong L., Li J., Yao Y., Ge S., Xu G. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829–838. - PMC - PubMed
    1. Jager K.J., Kramer A., Chesnaye N.C., Couchoud C., Sánchez-Álvarez J.E., Garneata L., Collart F., Hemmelder M.H., Ambühl P., Kerschbaum J. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98(6):1540–1548. - PMC - PubMed
    1. Petrilli C.M., Jones S.A., Yang J., Rajagopalan H., O’Donnell L., Chernyak Y., Tobin K.A., Cerfolio R.J., Francois F., Horwitz L.I. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. bmj. 2020;369 - PMC - PubMed
    1. Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E., Curtis H.J., Mehrkar A., Evans D., Inglesby P., Cockburn J., McDonald H.I., MacKenna B., Tomlinson L., Douglas I.J., Rentsch C.T., Mathur R., Wong A.Y.S., Grieve R., Harrison D., Forbes H., Schultze A., Croker R., Parry J., Hester F., Harper S., Perera R., Evans S.J.W., Smeeth L., Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436. - PMC - PubMed